conclusions this study supports the idea that the ifnl3 gene is an important predictor of the response of chb patients to ifn therapy. results nine studies of 1602 chb patients receiving ifn treatment were included. under the random-effects model, patients expressing the variant rs12980275 showed a significantly increased response to ifn therapy (or = 2.85; 95% ci = 1.14 - 4.60). in the subgrou...

conclusions cyp27b1-1260 polymorphism is associated with abnormal glucose metabolism in hcv infected patients. hcv infected individuals with cyp27b1-1260 genotype cc appeared to have an increased risk of developing abnormal fpg levels. results in hcv infected patients with abnormal fpg levels, the frequency of the genotype cc was significantly higher than that in patients with normal fpg levels...

objective: chronic infection of hepatitis b and hepatitis c are considered as the most important infectious diseases, which lead to drastic consequences such as liver dysfunction. depression is a psychiatric disorder which is concomitantly present in these patients, and decreases the patients’ quality of life. it may lead to suicide, homicide or intentional transmission of infectious to others....

OBJECTIVE To determine whether statins affect type 1 interferon responses in relapsing-remitting multiple sclerosis (RRMS). DESIGN Study effects of atorvastatin on type 1 interferon responses in Jurkat cells, mononuclear cells (MNCs) from therapy-naive patients with RRMS in vitro, and MNCs from interferon-treated RRMS patients in vivo in 4 conditions: no drug, statin only, interferon-beta onl...

Recent advances in the treatment of hepatitis C virus (HCV) infection have led to the availability of both highly efficacious interferon-containing and interferon-sparing regimens. However, the use of such therapies faces restrictions due to high costs. For patients who are medically eligible to receive interferon, the choice between the two will likely be impacted by preferences surrounding in...

abstract background: combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis c today. the aim of this study was to evaluate the efficacy and safety of thrice-weekly heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis c. methods: a total of97 treatment-naive patients received heberon three millio...

Interferon is being increasingly used in the treatment of chronic hepatitis C. Several case reports have suggested an association between interferon therapy and sarcoidosis with hypercalcemia. We report a case of severe hypercalcemic crisis with bilateral hilar lymphadenopathy in a male patient who was receiving interferon therapy for hepatitis C. Gastroenterologists should be aware of this unu...

Little is known about the optimal treatment following the initial failure of interferon therapy and the potential different efficacy with de novo therapy with entecavir (ETV) or telbivudine (LDT) and following the interferon therapy failure.ETV or LDT therapy following the interferon therapy failure was compared with that of de novo therapy with ETV or LDT in patients with chronic hepatitis B v...